Biotech | April 06, 2022
Singlera Genomics announces research collaboration with Astellas Pharma
The aim is to pursue methylation-based tools to better understand biological reactions to pharmaceuticals
The aim is to pursue methylation-based tools to better understand biological reactions to pharmaceuticals
Under the terms of the agreement, Vipergen will apply its in-living-cell DNA-encoded library (DEL) screening platform to discover novel small-molecule compounds that bind to a selected Theseus kinase target
Lupin is committed to providing new affordable treatment options to healthcare providers and patients
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
The new structure further transitions the Health Care business line into a system solutions partner for the pharmaceutical and biotech industries
BVX-0922 to target colorectal cancer under investigator-sponsored IND
A major unresolved question in the field, however, is how do this machinery rapidly searches for and finds rare stretches of damage amid the "vast fields" of undamaged DNA
Subscribe To Our Newsletter & Stay Updated
